Dead Immature Dendritic Cell Vaccines for Scalable Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional vaccines using mature dendritic cells are costly and limited to self-sourced products, leading to high manufacturing complexity and low patient accessibility, while immature dendritic cells induce poor immunity, and live DCs are not universally applicable.
Innovation Solution
Development of a vaccine using antigen-sensitized immature dendritic cells, which can be exogenous, dead, and derived from different species, inducing an improved immune response through methods like sonication or lyophilization, reducing costs and increasing availability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines use mature dendritic cells, then immune response is induced, but manufacturing cost and complexity increase significantly
Solution Approach 1:
The patent uses immature dendritic cells as a simplified copy or alternative to mature dendritic cells. Instead of requiring the complex maturation process with multiple cytokine treatments, the invention uses immature DCs that can be more easily manufactured and scaled, while still achieving effective immune response when combined with appropriate adjuvants or antigen presentation methods
Solution Approach 2:
The patent changes the maturation state parameter of dendritic cells from mature to immature. By adjusting the differentiation and maturation parameters during manufacturing, the process becomes simpler and more scalable while maintaining immunogenicity through alternative mechanisms such as in situ maturation or adjuvant-mediated activation
2Reliability
If live dendritic cells are used in vaccines, then immune response is enhanced, but product availability and accessibility decrease
Solution Approach 1:
The patent employs immature dendritic cells that can be produced more easily and at lower cost compared to mature DCs. These cells are processed and administered in a standardized manner, making the vaccine more accessible and scalable without requiring complex live cell maintenance and quality control infrastructure
Solution Approach 2:
The patent develops a universal platform using immature dendritic cells that can be applied to multiple disease indications. The immature DCs serve as a versatile carrier that can present various antigens and work with different adjuvants, making the vaccine platform broadly applicable across different therapeutic areas and patient populations
3Ease of manufacture
If immature dendritic cells are used in vaccines, then manufacturing cost decreases, but immune response quality deteriorates
Solution Approach 1:
The patent introduces adjuvants or other immunomodulatory components as intermediaries that bridge the gap between immature dendritic cells and effective immune response. These adjuvants stimulate the immature DCs to mature in situ or enhance their antigen-presenting capability, thereby maintaining immune response quality while utilizing the manufacturing advantages of immature cells
Solution Approach 2:
The patent performs preliminary antigen loading or modification on immature dendritic cells during manufacturing, preparing them in advance for effective immune response upon administration. This preliminary action ensures that the simplified immature DC platform can still achieve high-quality immunogenicity without requiring complex post-manufacturing maturation steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccine elicits an earlier and better immune response compared to mature dendritic cells, offering a cost-effective and universally applicable therapeutic option for various diseases.
Implementation Method 1
killing comprises sonication, heat treatment, lyophilization, or a combination thereof
Implementation Method 2
killing comprises sonication, heat treatment, lyophilization, or a combination thereof
Implementation Method 3
killing comprises sonication, heat treatment, lyophilization, or a combination thereof
Data Source
AI summary
Disclosed herein are antigen sensitized exogenous immature dendritic cells. The dendritic cell may also be dead. Antigen sensitized dead exogenous immature dendritic cells may be used to elicit an immune response or reactivate the immune system. Further provided are vaccines comprising the dead antigen sensitized exogenous immature dendritic cells, methods of formulating vaccines, methods of inducing an immune response in a patient, and methods of treating a disease and methods of disease prevention.